MedPath
HSA Approval

MEFRIL-250 CAPSULE 250 mg

SIN10125P

MEFRIL-250 CAPSULE 250 mg

MEFRIL-250 CAPSULE 250 mg

October 2, 1998

NAINA MOHAMED & SONS PRIVATE LIMITED

NAINA MOHAMED & SONS PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNAINA MOHAMED & SONS PRIVATE LIMITED
Licence HolderNAINA MOHAMED & SONS PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

**DOSAGE AND ADMINISTRATION:** Undesirable effects may be minimized by using the minimum effective dose for the shortest duration necessary to control symptoms. The oral dosage form of mefenamic acid may be taken with food if gastrointestinal upset occurs. Mild to moderate pain/rheumatoid arthritis/osteoarthritis in adults and adolescents over 14 years of age: 500 mg three times daily. Dysmenorrhea: 500 mg three times daily, to be administered at the onset of menstrual pain and continued while symptoms persist according to the judgment of the physician. Menorrhagia: 500 mg three times daily, starting with the onset of bleeding and associated symptoms and continued according to the judgment of the physician.

ORAL

Medical Information

**INDICATIONS AND USES:** Mefenamic acid capsules is used to relieve various types of pain such as: headache; body aches, rheumatoid arthritis, osteoarthritis; muscle and joint pains; toothache; sprains; painful menstruation (dysmenorrhea and menorrhagia); trauma-related pains.

**CONTRAINDICATIONS:** - Hypersensitivity to the active substance or any of the excipients - Inflammatory bowel disease. - History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. - Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). - Severe heart failure, hepatic failure and renal failure. - History of hypersensitivity reaction to other NSAIDs. - During the last trimester of pregnancy. - Treatment of pain after coronary artery bypass graft (CABG) surgery.

M01AG01

mefenamic acid

Manufacturer Information

NAINA MOHAMED & SONS PRIVATE LIMITED

MICRO LABS LTD

Active Ingredients

MEFENAMIC ACID

250 mg

Mefenamic acid

Documents

Package Inserts

Mefril-250 PI.pdf

Approved: January 17, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.